New agents in post-remission therapy.
The choice of post-remission therapy for patients with acute myeloid leukemia (AML) depends on age, response to initial therapy, and on disease-related biology. High-dose ara-C (HIDAC) is the standard chemotherapy-based post-remission treatment for younger AML patients, but diagnostic cytogenetics and genetic features may mandate an allogeneic stem cell transplant. While intensive chemotherapy has little utility, the optimal post-remission therapy for older adults remains unclear, though reduced-intensity conditioning allogeneic stem cell transplant is being used with increasing frequency.
Harvard Medical School, Boston, MA 02115, USA. rstone@partners.org
Richard M
RM
Stone
D000328:Adult; D000367:Age Factors; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine